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Abstract 
Despite significant advances in the last 30 years in reducing morbidity and mortality from 
heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based 
therapies, patients remain at a high risk of adverse cardiovascular outcomes. 
Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitors (ARNI), has 
been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and 
improve symptoms in patients with chronic, ambulatory, symptomatic HFrEF in a large, 
phase 3, multicentre, international, randomised controlled trial, PARADIGM-HF, when 
compared to the gold-standard angiotensin converting enzyme inhibitor, enalapril. This 
article will review the development of sacubitril/valsartan, the evidence for its use and its 
current and future role in the management of HFrEF. 
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 “If at first you don’t succeed, 
Try, try, try again.” 
Thomas H. Palmer, The Teacher’s Manual (1840) 
 
Introduction 
The publication in 1987 of the Results of the Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS) heralded the beginning of 30 years of landmark randomised 
controlled trials (RCT) demonstrating the benefits of neurohumoral antagonists such as 
angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), 
mineralocorticoid receptor antagonists (MRA) and beta-blockers in reducing the morbidity 
and mortality from heart failure with reduced ejection fraction (HFrEF).[1–3] Additional 
benefits in specific patients have also been demonstrated with implantable cardioverter 
defibrillators (ICD), cardiac resynchronisation therapy (CRT) and ivabradine, an inhibitor of 
the sinus node If current.[2,3] Despite this substantial progress, significant challenges 
remain, with an increasingly elderly population and the improvements in the survival from 
myocardial infarction thought to contribute to a rising prevalence of HFrEF.[4]  
 
Sacubitril/valsartan (previously known as LCZ696), a combined angiotensin receptor-
neprilysin inhibitor (ARNI), represents a significant breakthrough in the management of 
HFrEF. The results of the Prospective Comparison of ARNI with ACEI to Determine Impact on 
Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial were the first to 
demonstrate efficacy of a new class of medication over the gold-standard ACE inhibitor 
enalapril, in reducing mortality, risk of HF hospitalisation and symptoms in patients with 
chronic, symptomatic, ambulatory HFrEF.[5] This article will review the development of 
sacubitril/valsartan, the evidence for its use and its current and potential future role in the 
management of HFrEF. 
 
Natriuretic peptides and neprilysin 
Left ventricular systolic function, most commonly due to myocardial damage as a 
consequence of coronary artery disease, hypertension or both, and leading to sustained, 
pathological activation of the renin angiotensin aldosterone system (RAAS) and sympathetic 
nervous system (SNS), results in the syndrome of HFrEF (Figure 1). In an effort to ameliorate 
the deleterious effects of this dysfunctional activation of the RAAS and SNS, the body 
releases a group of vasoactive peptides known as the natriuretic peptides (NP) in response 
to distension of the atria and ventricles. The first of these, atrial natriuretic peptide (ANP) 
was discovered by de Bold and colleagues in 1981 following the observation that the 
intravenous administration of atrial extracts in rats resulted in a potent natriuretic and 
diuretic response.[6] Additional beneficial vasodilatory, anti-fibrotic and anti-hypertrophic 
properties have also been described in ANP, B-type natriuretic peptide (BNP) and C-type 
natriuretic peptide (CNP).[7]  
 
The potential to augment endogenous levels of NPs to harness their protective properties 
was therefore identified as a potential therapeutic strategy in HFrEF. Despite favourable 
haemodynamic and natriuretic effects, the administration of exogenous NPs has not been 
shown to reduce mortality or HF hospitalisation in patients with acutely decompensated 
HFrEF in a series of RCTs.[8–11]  
 
The alternative method to augment endogenous levels of NP is to prevent their clearance 
which occurs through 2 pathways; elimination via the NP clearance receptor (NPRC or 
NPRC3) or enzymatic degradation by neprilysin (also known as neutral endopeptidase 24.11 
[NEP], enkephalinase, vasopeptidase and atriopeptidase).[12] Neprilysin is a membrane 
bound endopeptidase found in various tissues, but predominantly in the kidney.[13] Along 
with the degradation of NPs, neprilysin plays a role in the degradation of a number of other 
vasodilatory peptides including adrenomedullin, bradykinin, substance-P, vasoactive 
intestinal peptide (VIP), calcitonin gene related peptide (CGRP), glucagon-like peptide 1 
(GLP-1) and apelin, all of which may be beneficial in the vasoconstrictive state of HFrEF 
(Figure 1).[14,15] Pharmacological inhibition of neprilysin activity, was therefore proposed 
as a potential therapeutic avenue to maximise the benefits of the body’s own protective NP 
system.  The question was, how best to achieve it? 
 
Neprilysin inhibitors 
The first neprilysin inhibitor, thiorphan, was reported in 1980 by Roques and colleagues, 
with subsequent formulations demonstrating favourable haemodynamic and hormonal 
responses in animal models.[16,17] Initial investigations in humans were promising; both 
oral (racecodotril and ecadotril) and intravenous (candoxatrilat) preparations were reported 
to stimulate natriuresis and diuresis along with increases in circulating plasma levels of 
ANP.[18–20] Unlike loop diuretics, this effect was not accompanied by a deleterious 
activation of the RAAS.[21] Furthermore, ecadotril and candoxatrilat resulted in reductions 
in pulmonary wedge pressure in patients with HFrEF.[18,20]  
 
However, the development of neprilysin inhibitors as monotherapy for both HFrEF and 
hypertension was halted after extended treatment with the oral prodrug candoxatril in 
patients with hypertension did not result in a sustained blood-pressure lowering effect.[22] 
It later transpired that the lack of any anti-hypertensive effect with neprilysin inhibitors 
when administered as monotherapy was secondary to the inhibition of breakdown, and 
therefore increased levels of, the vasoconstrictors angiotensin II and endothelin 1, thereby 
neutralising the augmentation of vasodilatory peptides by neprilysin inhibition.[23,24]  
 
Combined neprilysin and ACE inhibition 
On the basis of the results of the CONSENSUS and SOLVD-Treatment trials, ACE inhibitors 
had cemented their role as first-line disease-modifying therapy for patients with HFrEF. The 
addition of a neprilysin inhibitor to an ACE inhibitor (i.e. combined neprilysin and RAAS 
blockade) was felt to be the logical answer to the issues with neprilysin inhibitor 
monotherapy and this gave rise to a class of medications known as vasopeptidase inhibitors. 
Of these, omapatrilat was the most extensively investigated.[25] The IMPRESS (Inhibition of 
Metalloprotease by Omapatrilat in a Randomized Exercise and Symptoms Study in Heart 
Failure) trial in 573 patients with HFrEF reported a trend towards improved survival and 
reduced risk of admission for worsening HF with omapatrilat compared to the ACE inhibitor, 
lisinopril.[26] A subsequent large phase 3 RCT, the Omapatrilat versus Enalapril Randomized 
Trial of Utility in Reducing Events (OVERTURE), was conducted but showed that treatment 
with omapatrilat did not result in a significant reduction in the primary endpoint of all-cause 
mortality or HF hospitalisation when compared with enalapril 10mg twice daily.[27] 
However, potential benefit of vasopeptidase inhibitors was not excluded, with a significant 
9% reduction observed in the secondary endpoint of all-cause mortality and cardiovascular 
(CV) hospitalisation. Unfortunately, the incidence of angioedema was more common with 
omapatrilat compared to enalapril, and this finding was replicated in a trial of omapatrilat in 
patients with hypertension.[28] Each of ACE and neprilysin catabolise bradykinin, and 
enzyme inhibition results in reduced breakdown of bradykinin. Later it was also found that 
omapatrilat inhibits aminopeptidase p, the third key enzyme involved in bradykinin 
degradation.[29]  As well as having potent vasodilatory properties, bradykinin increases 
tissue permeability and fluid extravasation through increased prostaglandin concentrations. 
The risk of potentially life-threatening angioedema when the two (or three) enzymes were 
inhibited together, along with the lack of any significant benefit compared to ACE inhibitors, 
halted the further development of vasopeptidase inhibitors. 
 
Angiotensin receptor-neprilysin inhibitors 
Combined RAAS-neprilysin inhibition with an angiotensin receptor blocker in place of an ACE 
inhibitor offered the theoretical benefit of this two-pronged approach whilst circumventing 
the issue with dual (or triple in the case of omapatrilat) inhibition of bradykinin metabolism 
and risk of angioedema associated with vasopeptidase inhibitors. It was with this in mind, 
that led to the development of a new class of medications known as angiotensin receptor-
neprilysin inhibitors (ARNI).  
 
Sacubitril/valsartan is the first-in-class ARNI, comprising of molecular moieties of valsartan 
(ARB) and a neprilysin inhibitor prodrug, sacubitril (AHU377).[30] Upon ingestion, sacubitril 
is rapidly metabolised into an active neprilysin inhibitor, sacubitrilat (LBQ657). 
Pharmacokinetic and pharmacodynamic studies of the target dose of 97/103mg BD, 
reported equivalent plasma concentrations of valsartan as valsartan 160mg BD (the dose 
studied in the Valsartan Heart Failure Trial [Val-HeFT]) and rises in cyclic guanosine 
monophosphate (cGMP) representing an increase in ANP secondary to effective neprilysin 
inhibition.[31,32] Importantly, the risk of angioedema with an ARNI was thought to be lower 
due to the discovery that sacubitrilat does not inhibit aminopeptidase p, unlike 
omapatrilat.[29] 
 
PARADIGM-HF compared sacubitril/valsartan (target dose 97/103mg twice daily) to the 
gold-standard ACE inhibitor, enalapril (target dose 10mg BD), in reducing the primary 
composite endpoint of CV death or HF hospitalisation in patients with chronic, ambulatory, 
symptomatic HFrEF.[5,33,34] Prior to randomisation, all patients underwent a mandatory 6-
8 week active run-in period to ensure tolerance of firstly enalapril 10mg BD, followed by 
sacubitril valsartan 97/103mg BD.[33] If no unacceptable side-effects occurred, patients 
were then randomised 1:1 to double-blind treatment with sacubitril/valsartan 97/103mg BD 
or enalapril 10mg BD. In March 2014, on the recommendation of the data-safety monitoring 
board, the trial was terminated early after a median follow-up of 27 months due to 
overwhelming evidence of benefit with treatment of sacubitril/valsartan compared to 
enalapril.  
 
Sacubitril/valsartan was associated with a twenty percent reduction in the composite 
primary endpoint of CV death or HF hospitalisation compared to treatment with enalapril 
(hazard ratio [HR] 0.80; 95% confidence interval [CI], 0.73-0.87; p<0.001 [Figure 2]).[5] 
Significant reductions in both components of the primary endpoint, CV death and HF 
hospitalisation, were reported with HR of 0.80 (95% CI 0.71-0.89; p<0.001) and 0.79 (95% CI 
0.71-0.89; p<0.001), respectively (Figure 2). The two predominant modes of CV death, 
sudden and pump-failure death, were significantly reduced to a similar degree.[35] The 
secondary endpoint of all-cause mortality was also significantly reduced in the 
sacubitril/valsartan group (HR 0.84; 95% CI, 0.76 to 0.93; p<0.001).[5] The benefit seen with 
sacubitril/valsartan was consistent across all prespecified sub-groups.[5] These results mean 
that for every 1000 patients converted from enalapril to sacubitril, 46 fewer primary 
endpoints, 31 fewer CV deaths, 27 fewer patients hospitalised with worsening HF (and 52 
fewer total HF hospitalisations), and 28 fewer deaths from any cause would occur over a 
median of 27 months.  
 
Sacubitril/valsartan was well tolerated with low rates of discontinuation due to adverse 
effects (Figure 3).[5] The presence of an active run-in period prior to randomisation ensured 
initial tolerability and maximised the number of patients able to attain target doses of both 
study drugs. Angioedema was numerically more common with sacubitril/valsartan than 
enalapril (19 [0.5%] cases vs. 10 [0.2%]) however this difference did not reach statistical 
significance (p=0.13).  Additionally, no cases of angioedema with associated airway 
compromise were reported. There was a statistically significant difference (p<0.001) in the 
occurrence of symptomatic hypotension with sacubitril/valsartan (14%) compared to 
enalapril (9%), but this rarely resulted in treatment discontinuation (0.9% vs. 0.7% 
respectively; p=0.38). The occurrence of elevations in serum creatinine (≥2.5mg/dl), 
potassium(>6mmol/l), and cough was less frequent with sacubitril/valsartan than enalapril. 
 
Subsequent to the publication of the main results of PARADIGM-HF, a variety of additional 
analyses have been published, giving further insight into the benefits of sacubitril/valsartan 
in patients with HFrEF. In an analysis of the treatment effect by age, the benefit of 
sacubitril/valsartan was seen to extend to all age groups with no difference in the risk of 
adverse events.[36] The efficacy of sacubitril/valsartan was consistent across the range of 
left ventricular ejection fractions reported, as well as the baseline risk assessed by clinical 
risk-scores.[37,38] Patients with HFrEF often experience recurrent admissions to hospital 
(approximately one-third of the PARADIGM-HF cohort) resulting in a significant burden on 
patients; sacubitril/valsartan not only reduces the risk of first events but also that of 
recurrent HF hospitalisations and/or CV death.[39] Hospital readmissions for any cause or 
HF occurring within 30 days of an admission were also reduced significantly by 
sacubitril/valsartan and this benefit persisted when 60 day readmissions were assessed.[40] 
Furthermore, patients randomised to sacubitril/valsartan benefited from reductions in the 
risk of emergency department visits and/or outpatient intensification of medical 
therapy.[41,42] 
 
Implementation of sacubitril/valsartan into clinical practice 
Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory 
approval for use in patients who conform to the main inclusion criteria of the trial; NYHA 
functional class II-IV, reduced left ventricular ejection fraction (<40%), receiving guideline 
recommended treatment with a beta-blocker and MRA, a systolic blood pressure of ≥100 
mm Hg, estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 and potassium 
≤5.2 mmol/L.[43,44] The requirement for elevated NP levels for trial inclusion was omitted 
from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
prescribing information, reflecting that the majority of patients with HFrEF have elevated NP 
levels and furthermore, no interaction with treatment effect and baseline NP levels was 
reported.[5]  
 Regulatory approval of new drugs requires confirmation of clinical efficacy in two trials with 
a two-sided p-value of <0.05 or alternatively, a single, large, internally consistent 
multicentre study with p<0.00125. PARADIGM-HF met these criteria with overwhelming 
statistical evidence of efficacy; its p value for the primary endpoint was 0.0000004 which is 
equivalent to 4-5 trials with p value <0.05 and the likelihood of demonstrating the 
treatment effect observed, if in fact sacubitril/valsartan was no better than enalapril, is less 
than one in a million.[45] Given this, we believe it would be unethical to perform a second 
trial in HFrEF with sacubitril/valsartan. The degree of statistical robustness of the results of 
PARADIGM-HF posed an interesting quandary to the committees of international HFrEF 
guidelines; usually a solitary trial would be afforded a B level of evidence, however it could 
be argued that the results of PARADIGM-HF prove beyond reasonable doubt the efficacy of 
sacubitril/valsartan over enalapril at reducing morbidity and mortality in HFrEF.  
Furthermore, a meta-analysis combining all trials investigating dual neprilysin and RAAS 
inhibition in HFrEF (IMPRESS, OVERTURE and PARADIGM-HF) reported a significant pooled 
HR of 0.86 (95% CI 0.76-0.97; p = 0.013) in favour of dual neprilysin/RAAS inhibition 
compared to ACE inhibition for the composite outcome of all-cause death or HF 
hospitalisation.[46]  
 
The European Society of Cardiology (ESC) and American College of Cardiology (ACC) 
guideline committees have both awarded a Class 1B recommendation for 
sacubitril/valsartan to reduce the risk of HF hospitalisation and death in HFrEF patients who 
remain symptomatic despite treatment with an ACE inhibitor or ARB, beta-blocker and 
MRA.[2,47] ESC guidelines maintain that patients should be established on an ACE inhibitor 
or ARB for a minimum of one-month prior to switching to sacubitril/valsartan however ACC 
guidance is less strict regarding this, permitting initiation in ACE inhibitor/ARB naïve 
patients.[2,44,47] This more liberal approach has some support from the results of the 
TITRATION study examining two initiation and up-titration regimens for sacubitril/valsartan; 
7% of patients were ACE inhibitor/ARB naïve, reporting equivalent rates of adverse events 
to the total population.[48] A small proportion of this cohort were hospitalised patients 
(11%) and further information regarding the safety of initiation of sacubitril/valsartan in this 
group will be provided by two on-going trials in patients stabilised following an acute 
decompensation of HFrEF (PIONEER-HF; ClinicalTrials.gov ID NCT02554890 and TRANSITION; 
NCT02661217). The observation in PARADIGM-HF that sacubitril/valsartan was associated 
with lower rates of renal dysfunction and hyperkalaemia (including in those prescribed an 
MRA at baseline or those who commenced an MRA during follow-up) may translate into a 
higher proportion of patients being able to achieve optimal RAAS inhibition (as well as the 
additional benefits associated with concomitant neprilysin inhibition) with initiation of an 
ARNI rather than an ACE inhibitor or ARB.[49] 
 
What next for sacubitril/valsartan? 
A wide-ranging portfolio of post-regulatory approval trials and observational studies are 
underway to further establish the role and safety of sacubitril/valsartan in clinical practice 
as well as helping to deepen our understanding into the mechanism of action of ARNIs. 
These are summarised in Table 1.  
 
Two of these deserve further mention; the first, the Prospective Comparison of ARNI with 
ARB Global Outcomes in HF With Preserved Ejection Fraction (PARAGON-HF) trial will 
compare sacubitril/valsartan to valsartan in patients with heart failure and preserved 
ejection fraction (HFpEF) and the effect on morbidity and mortality in this group of patients 
in which there is currently no evidenced-based treatments.[50] This subject is further 
discussed by Senni in this issue [REFERENCE TO ARTICLE] and the results of PARAGON-HF 
are expected in 2019.  
 
The second, the Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in 
Reducing Heart Failure Events After MI (PARADISE-MI; NCT02924727), will assess the effect 
of sacubitril/valsartan compared to ramipril in patients with left ventricular systolic 
dysfunction and/or pulmonary congestion following acute myocardial infarction. This 
population are at high risk of developing symptomatic HFrEF in the future, as evidenced by 
the high prevalence of prior myocardial infarction in the PARADIGM-HF cohort (43%).[5] 
PARADISE-MI will provide evidence for the role of sacubitril/valsartan in the continuum of 
risk from acute myocardial infarction to symptomatic chronic HFrEF in a similar manner to 
previous trials have for ACE inhibitors and ARB.[51] 
 
The implementation of any new medication into routine clinical practice is dependent on a 
variety of factors, including cost-effectiveness. A variety of economic analyses in a variety of 
health-care systems have been reported, with sacubitril/valsartan representing a cost-
effective option compared to enalapril at reducing morbidity and mortality, along with 
improving quality of life in patients with HFrEF.[52,53] Optimal implementation of 
sacubitril/valsartan in the United States of America (USA) has been projected to prevent 
over 28 000 deaths per year.[54] Despite this, there has been significant inertia with the 
uptake of sacubitril/valsartan into clinical practice; in the 18 months following FDA approval, 
<3% of patients in a USA cohort with HFrEF were prescribed sacubitril/valsartan.[55] Various 
reasons have been suggested to be contributing to this, including the belief that if patients 
are stable on an ACE inhibitor (or an ARB) then there is no reason to switch to an ARNI. 
Evidence from PARADIGM-HF would suggest otherwise; “stable” patients, those without a 
HF hospitalisation in the 3 months prior to screening or no history of HF hospitalisation, are 
at high risk of adverse outcomes and benefit from sacubitril/valsartan as much as recently 
hospitalised patients.[56]  
 
Summary 
The results of PARADIGM-HF represent the most significant breakthrough in the 
management of heart failure of the last decade. Sacubitril/valsartan, a first in class ARNI, is 
the first medication, when compared head-to-head with the gold standard ACE inhibitor, 
enalapril, to demonstrate superiority in reducing the risk of cardiovascular outcomes and 
symptoms for patients with HFrEF. We believe, therefore, that an ARNI should replace an 
ACE inhibitor (or an ARB) in patients with symptomatic HFrEF, a view reflected in the most 
recent international HF guidelines.[2,47] Adoption of this life-saving treatment, however, 
has been slow and the onus is on clinicians to act, in order to improve their patient’s quality 
of life and reduce further morbidity and mortality. Ongoing studies will provide evidence 
regarding the role of sacubitril/valsartan in patients at high risk following a myocardial 
infarction (PARADISE-MI) and in patients with HFpEF (PARAGON-HF). 
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Table 1: Ongoing post-regulatory approval clinical trials with sacubitril/valsartan in heart failure 
ClinicalTrials.gov 
Identifier 
Study Title Summary 
NCT02970669 AWAKE-HF RCT comparing sacubitril/valsartan to enalapril and effect on measures of waking and sleep activity 
NCT02787798 B2AN-SNS RCT comparing sacubitril/valsartan to ACE inhibitor or ARB and effect on sympathetic nervous system activity 
NCT03359967 CHILISALT Open label cohort study evaluating changes in intrathoracic impedance after treatment with sacubitril/valsartan 
NCT02768298 CLCZ696BDE01 RCT comparing sacubitril/valsartan to enalapril and effect on exercise capacity 
NCT02916160 ENTRESTO-SAS  Open label cohort study in patients with sleep apnoea syndrome evaluating the effect of sacubitril/valsartan on the Apnoea Hypopnea 
Index 
NCT02874794 EVALUATE-HF RCT comparing sacubitril/valsartan to enalapril and effect on aortic wall stiffness  
NCT02816736 LIFE RCT comparing sacubitril/valsartan to valsartan and effect on NT-proBNP levels in NYHA IV HFrEF 
NCT03190304 NEPRIExTol RCT comparing sacubitril/valsartan to enalapril and effect on exercise capacity 
NCT02900378 OUTSTEP-HF RCT comparing sacubitril/valsartan to enalapril and effect on levels of non-sedentary physical activity measured by an accelerometer 
NCT02226120 PARADIGM-HF Open Label Open label cohort study evaluating safety and tolerability of sacubitril/valsartan  
NCT02924727 PARADISE-MI RCT comparing sacubitril/valsartan to ramipril on CV outcomes in patients post AMI with LVSD and/or pulmonary congestion 
NCT03119623 PARADOR RCT comparing sacubitril/valsartan to enalapril and effect on endothelial function 
NCT01920711 PARAGON-HF RCT comparing sacubitril/valsartan to valsartan on cardiovascular outcomes in HFpEF 
NCT02468232 PARALLEL-HF RCT comparing sacubitril/valsartan to enalapril on CV outcomes in Japanese patients 
NCT02690974 PARASAIL Open label cohort study describing safety and tolerability of sacubitril/valsartan 
NCT02788656 PARENT RCT comparing sacubitril/valsartan to ACE inhibitor or ARB and effect on pulmonary artery pressure measured by CardioMEMs 
NCT02884206 PERSPECTIVE RCT comparing sacubitril/valsartan to valsartan and effect on cognitive function in HFpEF 
NCT02554890 PIONEER-HF RCT comparing sacubitril/valsartan to enalapril and effect on NT-proBNP levels in patients stabilised following hospitalisation for 
acutely decompensated HFrEF 
NCT02687932 PRIME RCT comparing sacubitril/valsartan to valsartan and effect on functional mitral regurgitation severity 
NCT02887183 PROVE-HF Open label cohort study exploring relationship between changes in biomarkers and cardiac remodelling parameters, patient-reported 
outcomes and cardiovascular outcomes. 
NCT02661217 TRANSITION Open label RCT comparing two modalities of treatment initiation (pre-discharge, and post-discharge) with sacubitril/valsartan in 
patients stabilised following hospitalisation for acutely decompensated HFrEF 
NCT03300427 TurkuPET RCT comparing sacubitril/valsartan to valsartan and effect on cardiac oxygen consumption and efficiency of cardiac work 
NCT03168568 VASCEND RCT comparing sacubitril/valsartan to valsartan and effect on flow-mediated vasodilation  
 
 
Unless otherwise specified, trial populations are patients with heart failure with reduced ejection fraction (HFrEF). 
Abbreviations: ACE, angiotensin converting enzyme; AMI, acute myocardial infraction; ARB, angiotensin receptor blocker; CV, cardiovascular; 
HFpEF, heart failure with preserved ejection fractions; LVSD, left ventricular systolic dysfunction; NT-proBNP, N-terminal pro brain natriuretic 
peptide; NYHA, New York Heart Association; RCT, randomised controlled trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Neurohumoral pathway activation in heart failure with reduced ejection fraction and targets for ACE inhibitors, ARB, MRA, beta-
blockers and ARNI. 
 
 
 
Blue arrows denote activating pathways and red arrows denote inhibitory pathways. 
Abbreviations: ACE, angiotensin converting enzyme; ANP, atrial natriuretic peptide; ARNI, angiotensin receptor-neprilysin inhibitor; AT1R, 
angiotensin type 1 receptor; BNP, brain natriuretic peptide; CGRP, calcitonin gene related peptide; CNP, C-type natriuretic peptide; GLP-1, 
glucagon-like peptide 1; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; VIP, vasoactive 
intestinal peptide. 
Figure 2: PARADIGM-HF: Kaplan–Meier Curves for outcomes according to randomised treatment 
 
Hazard ratios, 95% confidence intervals and two-sided p values were calculated using Cox proportional-hazards models, with treatment and 
region as fixed-effect factors.  
Abbreviations: CI, confidence interval; CV, cardiovascular; HF, heart failure. 
 
Figure 3: Summary of adverse events in PARADIGM-HF – comparison of sacubitril/valsartan with enalapril. 
 
Summary of the adverse events after randomisation in PARADIGM-HF – comparison of sacubitril/valsartan with enalapril. * denotes p<0.05. 
Abbreviations: SBP, systolic blood pressure. 
 
